Effects of intraarticular treatment with stanozolol on synovial membrane and cartilage in an ovine model of osteoarthritis.
Aim of the study was to verify the clinical and morphological effects of intra-articular stanozolol or placebo treatment, lasting 3 and 9 months, in sheep in which a femoro-tibial osteo-arthritis (OA) were surgically induced (medial bilateral meniscectomy). Twenty healthy sheep divided into four groups and two control animals group, after surgical medial bilateral meniscectomy, were weekly injected in femoral-tibial joint (FTJ) with stanozolol or placebo. Lameness evaluation was performed and synovial fluid was collected from all sheep at each treatment time. Necropsies were performed after 3 or 9 month as described in experimental design. Gross pathologies were described and specimen tissues collected from femoro-tibial articular joints were processed for routine histological examination. The gross anatomy of the FTJ was well-preserved in stanozolol-treated sheep; this also applied to the histological features of articular cartilage. Joint aseptic inflammation and fibrosis were observed in placebo-treated sheep, associated with a different degree of severity of condylar and tibial plate cartilage degeneration. Stanozolol intra-articular treatment reduces osteophytes formation and subchondral bone reaction and promotes articular cartilage regeneration.
Department of Veterinary Medical Sciences, Alma Mater University of Bologna, Italy.
A
A
Spadari
N
N
Romagnoli
P G
PG
Predieri
P
P
Borghetti
A M
AM
Cantoni
A
A
Corradi
D045930:Anabolic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002356:Cartilage / Q000187:drug effects* / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D007270:Injections, Intra-Articular; D007794:Lameness, Animal / Q000188:drug therapy / Q000209:etiology; D010003:Osteoarthritis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy* / Q000473:pathology; D013197:Stanozolol / Q000008:administration & dosage / Q000627:therapeutic use*; D013582:Synovial Fluid / Q000187:drug effects; D013583:Synovial Membrane / Q000187:drug effects* / Q000473:pathology
D045930:Anabolic Agents; D013197:Stanozolol